Meeting
2017 ASCO Annual Meeting
KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Authors
Jean-Pascal H. Machiels
Cliniques Universitaires Saint-Luc, Brussels, Belgium
Jean-Pascal H. Machiels , Lisa Licitra , Danny Rischin , John Waldron , Barbara Burtness , Vincent Gregoire , Tulin Shekar , Holly M. Brown , Jonathan D. Cheng , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03040999
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS6090)
DOI
10.1200/JCO.2017.35.15_suppl.TPS6090
Abstract #
TPS6090
Poster Bd #
78a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase IB study of pembrolizumab in combination with chemoradiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
First Author: Steven Francis Powell
Poster
2018 ASCO Annual Meeting
Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.
First Author: Jean-Pascal H. Machiels
Poster
2024 ASCO Annual Meeting
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.
First Author: Manabu Muto
Poster
2023 ASCO Annual Meeting
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
First Author: Robert L. Ferris